PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones.

Parallel artificial membrane permeability assay (PAMPA) was used to measure the effective permeability, P(e), as a function of pH from 4 to 10, of 17 fluoroquinolones, including three congeneric series with systematically varied alkyl chain length at the 4'N-position of the piperazine residue. The permeability values spanned over three orders of magnitude. The intrinsic permeability, P(o), and the membrane permeability, P(m), were determined from the pH dependence of the effective permeability. The pK(a) values were determined potentiometrically. The PAMPA method employed stirring, adjusted such that the unstirred water layer (UWL) thickness matched the 30-100 microm range estimated to be in the human small intestine. The intrinsic permeability coefficients (10(-6)cm/s), representing the permeability of the uncharged form of the drug, are for 4'N-R-norfloxacin: 0.7 (R=H), 49 (Me), 132 (n-Pr), 365 (n-Bu); 4'N-R-ciprofloxacin: 2.7 (H), 37 (Me), 137 (n-Pr), 302 (n-Bu); 4'N-R-3'-methylciprofloxacin: 3.8 (H), 20 (Me), 51 (Et), 160 (n-Pr), 418 (n-Bu). Increasing the alkyl chain length in the congeneric series resulted in increased permeability, averaging about 0.34 log units per methylene group, except that of the first (H-to-Me), which was about 1.2 log units. These results were compared to Caco-2 and rat in situ permeability measurements. The in situ closed loop technique used for obtaining permeability values in rat showed a water layer thickness effect quite consistent with in vivo expectations. The rat-PAMPA correlation (r2=0.87) was better than that of rat-Caco-2 (r2=0.63). Caco-2-PAMPA correlation indicated r2=0.66. The latter correlation improved significantly (r2=0.82) when the Caco-2 data were corrected for the UWL effect.

[1]  A. Avdeef High‐throughput Measurement of Permeability Profiles , 2004 .

[2]  P. Artursson,et al.  A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelial caco 2 cells grown in permeable filter chambers , 1991 .

[3]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[4]  A. Walter,et al.  Monocarboxylic acid permeation through lipid bilayer membranes , 2005, The Journal of Membrane Biology.

[5]  L. Dittert,et al.  Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. , 1969, Journal of pharmaceutical sciences.

[6]  Bradley D Anderson,et al.  A hydrophobicity scale for the lipid bilayer barrier domain from peptide permeabilities: nonadditivities in residue contributions. , 2003, Biochemistry.

[7]  J. Huneau,et al.  Secretion of Sparfloxacin from the Human Intestinal Caco-2 Cell Line Is Altered by P-Glycoprotein Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[8]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[9]  A. Avdeef,et al.  Accurate measurements of the concentration of hydrogen ions with a glass electrode: calibrations using the Prideaux and other universal buffer solutions and a computer-controlled automatic titrator , 1978 .

[10]  Gerd Folkers,et al.  Pharmacokinetic optimization in drug research , 2001 .

[11]  N. Yata,et al.  Studies on absorption of drugs. 8. Physicochemical factors affecting the absorption of sulfonamides from the rat small intestine. , 1973, Chemical & pharmaceutical bulletin.

[12]  Ming Hu,et al.  Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. , 2002, Journal of pharmaceutical sciences.

[13]  G Folkers,et al.  Shapes of membrane permeability-lipophilicity curves: extension of theoretical models with an aqueous pore pathway. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[15]  A. Dantzig,et al.  Mechanism and Kinetics of Transcellular Transport of a New β-Lactam Antibiotic Loracarbef Across an Intestinal Epithelial Membrane Model System (Caco-2) , 2004, Pharmaceutical Research.

[16]  A. Pozo,et al.  Studies on the reliability of a bihyperbolic functional absorption model. I. Ring-substituted anilines , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  Kiyohiko Sugano,et al.  Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. , 2002, International journal of pharmaceutics.

[18]  M. Bermejo,et al.  Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones. , 2000, Journal of pharmaceutical sciences.

[19]  M. Bermejo,et al.  Validation of a biophysical drug absorption model by the PATQSAR system. , 1999, Journal of pharmaceutical sciences.

[20]  Thomas J. Raub,et al.  Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. , 1995, Journal of pharmaceutical sciences.

[21]  Han van de Waterbeemd,et al.  Drug bioavailability : estimation of solubility, permeability, absorption and bioavailability , 2003 .

[22]  M. Machida,et al.  High Throughput Prediction of Oral Absorption: Improvement of the Composition of the Lipid Solution Used in Parallel Artificial Membrane Permeation Assay , 2001, Journal of biomolecular screening.

[23]  Kin-Kai Hwang,et al.  A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. , 2002, European journal of medicinal chemistry.

[24]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[25]  M. A. Cabrera Pérez,et al.  A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  A. Avdeef,et al.  PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Alex Avdeef,et al.  Absorption and Drug Development: Solubility, Permeability, and Charge State , 2003 .

[28]  K. Terada,et al.  Optimized conditions of bio-mimetic artificial membrane permeation assay. , 2001, International journal of pharmaceutics.

[29]  T. Garrigues,et al.  Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones. , 1995, Journal of pharmaceutical sciences.

[30]  Alex Avdeef,et al.  In vitro trans-monolayer permeability calculations: often forgotten assumptions. , 2003, Drug discovery today.

[31]  R. Farinotti,et al.  Absorption of ofloxacin isomers in the rat small intestine , 1997, Antimicrobial agents and chemotherapy.

[32]  D. Winne,et al.  Closed rat jejunal segment in situ: role of pre-epithelial diffusion resistance (unstirred layer) in the absorption process and model analysis , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[34]  M. Bermejo,et al.  Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[36]  Y. Zhu,et al.  The Caco-2 cell monolayers as an intestinal metabolism model: metabolism of dipeptide Phe-Pro. , 1994, Journal of drug targeting.

[37]  G Folkers,et al.  Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  J. Prieto,et al.  Kinetic mechanism for the intestinal absorption of ofloxacin , 1988, The Journal of pharmacy and pharmacology.

[39]  B. Faller,et al.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. , 2001, Journal of medicinal chemistry.

[40]  L. Dittert,et al.  Drug absorption. 3. Effect of membrane storage on the kinetics of drug absorption. , 1970, Journal of pharmaceutical sciences.

[41]  M. Strafford,et al.  Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.